Novartis plans to build a EUR 35 million radioligand therapy production facility in Halle, eastern Germany, announced November 11, 2025, specializing in cancer therapies using radioligands1.
The German facility is expected to open in late 2027, with potential for future expansions, leveraging Germany's expertise in radioligand therapy1.
Recent Novartis expansions include new RLT sites in Winter Park, Florida (announced January 9, 2026, online by 2029) and Denton, Texas (announced February 25, 2026, operational in 2028)23.
No search results mention Germany stepping up a probe into Gerresheimer; available information focuses solely on Novartis' manufacturing announcements.
Sources:
1. https://www.gtai.de/en/invest/industries/energy/swiss-pharma-giant-plans-german-expansion-1944608
2. https://www.novartis.com/news/media-releases/novartis-add-radioligand-therapy-manufacturing-facility-winter-park-florida-fourth-us-serve-patients-and-advance-23-billion-investment
3. https://www.novartis.com/news/media-releases/novartis-build-new-radioligand-therapy-site-denton-texas-delivering-more-next-generation-treatments-patients